# Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

> **NCT04781855** · PHASE1 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Small Lymphocytic Lymphoma
- Richter Syndrome

## Interventions

- **DRUG:** Ibrutinib
- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT04781855
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-07-14
- **Primary completion:** 2025-02-21
- **Final completion:** 2025-02-21
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 0% Participants
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04781855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04781855, "Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04781855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*